Differential Expression of Candidate Virus Receptors in Human T Lymphocytes Prone or Resistant to Infection with Patient-Derived Hepatitis C Virus

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Sarhan, Mohammed A ^a   Chen, Annie Y ^a   Michalak, Tomasz I ^a  

^a MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CD5 ANTIGEN; CD81 ANTIGEN; CLAUDIN 1; CLAUDIN 6; OCCLUDIN; SCAVENGER RECEPTOR B; SCAVENGER RECEPTOR BI; VIRUS RECEPTOR; CD36 ANTIGEN; CLAUDIN; CLDN7 PROTEIN, HUMAN; OCLN PROTEIN, HUMAN;

ANIMAL CELL; ARTICLE; CELL STRAIN HEPG2; CONTROLLED STUDY; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; IMMUNE SYSTEM; IMMUNOBLOTTING; INFECTION RESISTANCE; INFECTION SENSITIVITY; LIVER CELL; LYMPHOCYTE; LYMPHOCYTE SUBPOPULATION; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T LYMPHOCYTE; UPREGULATION; CELL LINE; GENE EXPRESSION REGULATION; GENE SILENCING; GENETICS; HEPACIVIRUS; HEPATITIS C; JURKAT CELL LINE; METABOLISM; MONONUCLEAR CELL; PHYSIOLOGY; T LYMPHOCYTE SUBPOPULATION; VIROLOGY;

HEPATITIS C VIRUS;

ANTIGENS, CD36; ANTIGENS, CD5; ANTIGENS, CD81; CELL LINE; CLAUDINS; GENE EXPRESSION REGULATION; GENE KNOCKDOWN TECHNIQUES; HEPACIVIRUS; HEPATITIS C; HUMANS; JURKAT CELLS; LEUKOCYTES, MONONUCLEAR; OCCLUDIN; RECEPTORS, VIRUS; T-LYMPHOCYTE SUBSETS;

EID: 84876539710     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0062159     Document Type: Article

References (73)

1. World Health Organization (2004) Global burden of disease (GBD) for hepatitis C. J Clin Pharmacol. 44: 20-9.
2. Francisco M, Averhoff N, Glass AN, Holtzman D, (2012) Global burden of hepatitis C: considerations for healthcare providers in the United States. Clin Infect Dis 55(S1): 10-15.
3. Butt AA, Kanwal F, (2012) Boceprevir and telaprevir in the management of hepatitis C virus-infected patients. Clin Infect Dis 54: 96-104.
4. Lin K, Perni RB, Kwong AD, Lin C, (2006) VX-950, a novel hepatitis C virus (HCV) NS3-4A protease inhibitor, exhibits potent antiviral activities in HCV replicon cells. Antimicrob Agents Chemother 50: 1813-1822.
5. McHutchison JG, Manns MP, Muir AJ, Terrault NA, Jacobson IM, et al. (2010) Telaprevir for previously treated chronic HCV infection. N Engl J Med 362: 1292-1303.
6. Lindenbach BD, Meuleman P, Ploss A, Vanwolleghem T, Syder AJ, et al. (2006) Cell culture-grown hepatitis C virus is infectious in vivo and can be recultured in vitro. Proc Natl Acad Sci USA 103: 3805-3809.
7. Wakita T, Pietschmann T, Kato T, Date T, Miyamoto M, et al. (2005) Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 11: 791-796.
8. Zhong J, Gastaminza P, Cheng G, Kapadia S, Kato T, et al. (2005) Robust hepatitis C virus infection in vitro. Proc Natl Acad Sci USA 102: 9294-9299.
9. Bartosch B, Vitelli A, Granier C, Goujon C, Dubuisson J, et al. (2003) Cell entry of hepatitis C virus requires a set of co-receptors that include the CD81 tetraspanin and the SR-B1 scavenger receptor. J Biol Chem 278: 41624-41630.
10. Hsu M, Zhang J, Flint M, Logvinoff C, Cheng-Mayer C, et al. (2003) Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles. Proc Natl Acad Sci USA 100: 7271-7276.
11. Pileri P, Uematsu Y, Campagnoli S, Galli G, Falugi F, et al. (1998) Binding of hepatitis C virus to CD81. Science 282: 938-941.
12. Germi R, Crance J, Garin D, Guimet J, Lortat-Jacob H, et al. (2002) Cellular glycosaminoglycans and low density lipoprotein receptor are involved in hepatitis C virus adsorption. J Med Virol 68: 206-215.
13. Scarselli E, Ansuini H, Cerino R, Roccasecca RM, Acali S, et al. (2002) The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. EMBO J 21: 5017-5025.
14. Evans MJ, von Hahn T, Tscherne DM, Syder AJ, Panis M, et al. (2007) Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature 446: 801-805.
15. Benedicto I, Molina-Jimenez F, Bartosch B, Cosset F L, Lavillette D,et al. 2009. The tight junction-associated protein occludin is required for a postbinding step in hepatitis C virus entry and infection. J Virol 83: 8012-8020.
16. Ploss A, Evans MJ, Gaysinskaya VA, Panis M, You H, et al. (2009) Human occludin is a hepatitis C virus entry factor required for infection of mouse cells. Nature 457: 882-886.
17. Lupberger J, Zeisel MB, Xiao F, Thumann C, Fofana I, et al. (2011) EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy. Nat Med 17: 589-595.
18. Forton DM, Karayiannis P, Mahmud N, Taylor-Robinson SD, Thomas HC, (2004) Identification of unique hepatitis C virus quasispecies in the central nervous system and comparative analysis of internal translational efficiency of brain, liver, and serum variants. J Virol 78: 5170-5183.
19. Wilkinson J, Radkowski M, Laskus T, (2009) Hepatitis C virus neuroinvasion: identification of infected cells. J Virol 83: 1312-1319.
20. Ducoulombier D, Roque-Afonso AM, Di Liberto G, Penin F, Kara R, et al. (2004) Frequent compartmentalization of hepatitis C virus variants in circulating B cells and monocytes. Hepatology 39: 817-825.
21. Pham TNQ, King D, MacParland SA, McGrath JS, Reddy SB, et al. (2008) Hepatitis C virus replicates in the same immune cell subsets in chronic hepatitis C and occult infection. Gastroenterology 134: 812-822.
22. Shimizu YK, Iwamoto A, Hijikata M, Purcell RH, Yoshikura H, (1992) Evidence for in vitro replication of hepatitis C virus genome in a human T-cell line. Proc Natl Acad Sci USA 89: 5477-5481.
23. MacParland SA, Pham TNQ, Gujar SA, Michalak TI, (2006) De novo infection and propagation of wild-type Hepatitis C virus in human T lymphocytes in vitro. J Gen Virol 87: 3577-3586.
24. MacParland SA, Pham TNQ, Guy CS, Michalak TI, (2009) Hepatitis C virus persisting after clinically apparent sustained virological response to antiviral therapy retains infectivity in vitro. Hepatology 49: 1431-1441.
25. Sarhan MA, Pham TNQ, Chen AY, Michalak TI, (2012) Hepatitis C virus infection of human T lymphocytes is mediated by CD5. J Virol 86: 3723-3735.
26. Blackard JT, Kemmer N, Sherman KE, (2006) Extrahepatic replication of HCV: insights into clinical manifestations and biological consequences. Hepatology 44: 15-22.
27. Chuang SS, Liao YL, Chang ST, Hsieh YC, Kuo SY, et al. (2010) Hepatitis C virus infection is significantly associated with malignant lymphoma in Taiwan, particularly with nodal and splenic marginal zone lymphomas. J Clin Pathol 63: 595-598.
28. Giannini C, Giannelli F, Zignego AL, (2006) Association between mixed cryogtobulinemia, translocation (14;18), and persistence of occult HCV lymphoid infection after treatment. Hepatology 43: 1166-1167.
29. Kasama Y, Sekiguchi S, Saito M, Tanaka K, Satoh M, et al. (2010) Persistent expression of the full genome of hepatitis C virus in B cells induces spontaneous development of B-cell lymphomas in vivo. Blood 116: 4926-4933.
30. Richiardi L, De Marco L, Gillio-Tos A, Merletti F, Fiano V, et al. (2010) Persistent infection by HCV and EBV in peripheral blood mononuclear cells and risk of non-Hodgkin's lymphoma. Cancer Epidemiol 34: 709-712.
31. Kondo Y, Sung VM, Machida K, Liu M, Lai MM, (2007) Hepatitis C virus infects T cells and affects interferon-gamma signaling in T cell lines. Virology 361: 161-173.
32. Laskus T, Radkowski M, Wilkinson J, Vargas H, Rakela J, (2002) The origin of hepatitis C virus reinfecting transplanted livers: serum-derived versus peripheral blood mononuclear cell-derived virus. J Infect Dis 185: 417-421.
33. Okuda M, Hino K, Korenaga M, Yamaguchi Y, Katoh Y, et al. (1999) Differences in hypervariable region 1 quasispecies of hepatitis C virus in human serum, peripheral blood mononuclear cells, and liver. Hepatology 29: 217-222.
34. Radkowski M, Gallegos-Orozco JF, Jablonska J, Colby TV, Walewska-Zielecka B, et al. (2005) Persistence of hepatitis C virus in patients successfully treated for chronic hepatitis C. Hepatology. 41: 106-114.
35. Willems M, Peerlinck K, Moshage H, Deleu I, Van den Eynde C, et al. (1994) Hepatitis C virus-RNAs in plasma and in peripheral blood mononuclear cells of hemophiliacs with chronic hepatitis C: evidence for viral replication in peripheral blood mononuclear cells. J Med Virol 42: 272-278.
36. Pham TNQ, Coffin CS, Churchill ND, Urbanski SJ, Lee SS, et al. (2012) Hepatitis C virus persistence after sustained virological response to antiviral therapy in patients with or without past exposure to hepatitis B virus. J Viral Hepat 19: 103-111.
37. Pham TNQ, MacParland SA, Mulrooney PM, Cooksley H, Naoumov NV, et al. (2004) Hepatitis C virus persistence after spontaneous or treatment-induced resolution of hepatitis C. J Virol. 78: 5867-5874.
38. Pham TNQ, Mercer SE, Michalak TI, (2009) Chronic hepatitis C and persistent occult hepatitis C virus infection are characterized by distinct immune cell cytokine expression profiles. J Viral Hepat 16: 547-556.
39. Pham TNQ, MacParland SA, Coffin CS, Lee SS, Bursey FR, et al. (2005) Mitogen-induced upregulation of hepatitis C virus expression in human lymphoid cells. J Gen Virol 86: 657-666.
40. Bare P, Massud I, Parodi C, Belmonte L, Garcia G, et al. (2005) Continuous release of hepatitis C virus (HCV) by peripheral blood mononuclear cells and B-lymphoblastoid cell-line cultures derived from HCV-infected patients. J Gen Virol 86: 1717-1727.
41. Morsica G, Tambussi G, Sitia G, Novati R, Lazzarin A, et al. (1999) Replication of hepatitis C virus in B lymphocytes (CD19+). Blood 94: 1138-1139.
42. Laskus T, Radkowski M, Piasek A, Nowicki M, Horban A, et al. (2000) Hepatitis C virus in lymphoid cells of patients coinfected with human immunodeficiency virus type 1: evidence of active replication in monocytes/macrophages and lymphocytes. J Infect Dis 181: 442-448.
43. Ciurea A, Klenerman P, Hunziker L, Horvath E, Odermatt B, et al. (1999) Persistence of lymphocytic choriomeningitis virus at very low levels in immune mice. Proc Natl Acad Sci USA 96: 11964-11969.
44. Oldstone MB, (2009) Anatomy of viral persistence. PLoS Pathog. 5: e1000523.
45. Durand T, Di Liberto G, Colman H, Cammas A, Boni S, et al. (2010) Occult infection of peripheral B cells by hepatitis C variants which have low translational efficiency in cultured hepatocytes. Gut 59: 934-942.
46. Navas S, Martin J, Quiroga JA, Castillo I, Carreno V, (1998) Genetic diversity and tissue compartmentalization of the hepatitis C virus genome in blood mononuclear cells, liver, and serum from chronic hepatitis C patients. J Virol 72: 1640-1646.
47. Dahari H, Feliu A, Garcia-Retortillo M, Forns X, Neumann AU, (2005) Second hepatitis C replication compartment indicated by viral dynamics during liver transplantation. J Hepatol 42: 491-498.
48. Radkowski M, Wang LF, Vargas HE, Rakela J, Laskus T, (1998) Detection of hepatitis C virus replication in peripheral blood mononuclear cells after orthotopic liver transplantation. Transplantation 66: 664-666.
49. Coffin CS, Mulrooney-Cousins PM, van Marle G, Roberts JP, Michalak TI, et al. (2011) Hepatitis B virus quasispecies in hepatic and extrahepatic viral reservoirs in liver transplant recipients on prophylactic therapy. Liver Transpl 17: 955-962.
50. Buck M, Chojkier M, (1996) Muscle wasting and dedifferentiation induced by oxidative stress in a murine model of cachexia is prevented by inhibitors of nitric oxide synthesis and antioxidants. EMBO J 15: 1753-1765.
51. Jones SM, Howell KE, Henley JR, Cao H, McNiven MA, (1998) Role of dynamin in the formation of transport vesicles from the trans-Golgi network. Science 279: 573-577.
52. Buck M, Zhang L, Halasz NA, Hunter T, Chojkier M, (2001) Nuclear export of phosphorylated C/EBPbeta mediates the inhibition of albumin expression by TNF-alpha. EMBO J 20: 6712-6723.
53. Damm EM, Pelkmans L, Kartenbeck J, Mezzacasa A, Kurzchalia T, et al. (2005) Clathrin- and caveolin-1-independent endocytosis: entry of simian virus 40 into cells devoid of caveolae. J Cell Biol 168: 477-488.
54. Korenaga M, Okuda M, Otani K, Wang T, Li Y, et al. (2005) Mitochondrial dysfunction in hepatitis C. J Clin Gastroenterol. 39: S162-S166.
55. Kroemer G, Jaattela M, (2005) Lysosomes and autophagy in cell death control. Nat Rev Cancer 5: 886-897.
56. Wakita T, Pietschmann T, Kato T, Date T, Miyamoto M, et al. (2005) Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 11: 791-796.
57. Marukian S, Jones CT, Andrus L, Evans MJ, Ritola KD, et al. (2008) Cell culture-produced hepatitis C virus does not infect peripheral blood mononuclear cells. Hepatology 48: 1843-1850.
58. Sarhan MA, Chen AY, Russell RS, Michalak TI, (2012) Patient-derived hepatitis C virus and JFH-1 clones differ in their ability to infect human hepatoma cells and lymphocytes. J Gen Virol 93: 2399-2407.
59. Cormier EG, Tsamis F, Kajumo F, Durso RJ, Gardner JP, et al. (2004) CD81 is an entry coreceptor for hepatitis C virus. Proc Natl Acad Sci USA 101: 7270-7274.
60. Scarselli E, Ansuini H, Cerino R, Roccasecca RM, Acali S, et al. (2002) The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. EMBO J 21: 5017-5025.
61. Barth H, Cerino R, Arcuri M, Hoffmann M, Schurmann P, et al. (2005) Scavenger receptor class B type I and hepatitis C virus infection of primary tupaia hepatocytes. J Virol 79: 5774-5785.
62. Yamada E, Montoya M, Schuettler CG, Hickling TP, Tarr AW, et al. (2005) Analysis of the binding of hepatitis C virus genotype 1a and 1b E2 glycoproteins to peripheral blood mononuclear cell subsets. J Gen Virol 86: 2507-2512.
63. Zheng A, Yuan F, Li Y, Zhu F, Hou P, et al. (2007) Claudin-6 and claudin-9 function as additional coreceptors for hepatitis C virus. J Virol 81: 12465-12471.
64. Benedicto I, Molina-Jimenez F, Barreiro O, Maldonado-Rodriguez A, Prieto J, et al. (2008) Hepatitis C virus envelope components alter localization of hepatocyte tight junction-associated proteins and promote occludin retention in the endoplasmic reticulum. Hepatology 48: 1044-1053.
65. Liu S, Yang W, Shen L, Turner JR, Coyne CB, et al. (2009) Tight junction proteins claudin-1 and occludin control hepatitis C virus entry and are downregulated during infection to prevent superinfection. J Virol 83: 2011-2014.
66. Friedlein G, El Hage F, Vergnon I, Richon C, Saulnier P, et al. (2007) Human CD5 protects circulating tumor antigen-specific CTL from tumor-mediated activation-induced cell death. J Immunol 178: 6821-6827.
67. Toubi E, Kessel A, Peri R, Shmuel Z, Bamberger E, et al. (2004) Enhanced apoptosis of peripheral CD5-negative B lymphocytes from chronically hepatitis C virus-infected patients: reversal after antiviral treatment. J Virol 78: 11379-11384.
68. Zuckerman E, Kessel A, Slobodin G, Sabo E, Yeshurun D, et al. (2003) Antiviral treatment down-regulates peripheral B-cell CD81 expression and CD5 expansion in chronic hepatitis C virus infection. J Virol 77: 10432-10436.
69. Foley GE, Lazarus H, Farber S, Uzman BG, Boone BA, et al. (1965) Continuous culture of human lymphoblasts from peripheral blood of a child with acute leukemia. Cancer 18: 522-529.
70. Lusso P, Cocchi F, Balotta C, Markham P, Louie A, et al. (1995) Growth of macrophage-tropic and primary human immunodeficiency virus type 1 (HIV-1) isolates in a unique CD4+ T-cell clone (PM1): failure to downregulate CD4 and to interfere with cell-line-tropic HIV-1. J Virol 69: 3712-3720.
71. Guy CS, Rankin SL, Wang J, Michalak TI, (2008) Hepatocytes can induce death of contacted cells via perforin-dependent mechanism. Hepatology 47: 1691-1701.
72. Michalak TI, Hodgson PD, Churchill ND, (2000) Posttranscriptional inhibition of class I major histocompatibility complex presentation on hepatocytes and lymphoid cells in chronic woodchuck hepatitis virus infection. J Virol 74: 4483-4494.
73. Girish V, Vijayalakshmi A, (2004) Affordable image analysis using NIH Image/Image. J. Indian J Cancer 41: 47.